CVR - Coronavirus Vaccines R&D Roadmap

Milestone
4.1.b

Resource availability

In progress
High priority

Expand the availability of validated reagents, virus strains and stocks, and standardized serologic assays for studying a broader range of coronaviruses in animal models, with an initial focus on additional sarbecoviruses and a wider variety of MERS-related merbecoviruses.

Progress Highlights

See CVR Scholar Hub page: Repositories for Coronavirus Research

BEI Resources is managed by ATCC and is under contract by the NIAID to identify, acquire, produce, store, deaccession, dispose of, and distribute biological and chemical research organisms and materials. They have a repository of hundreds of viral stocks, reagents, antigen preps, pseudoviruses, antibodies, etc. for coronavirus research.

The NIBSC and the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) have similar stocks of coronavirus research supplies.

Maren de Vries 2023 proposed a protocol for generating quality-controlled SARS-CoV-2 variant stocks that minimizes the acquisition of mutations and introduces stringent controls to detect them.